APOBEC3A, APOBEC3B, and APOBEC3H Haplotype 2 Restrict Human T-Lymphotropic Virus Type 1

Journal of Virology

Volumn 86, Issue 11, 2012, Pages 6097-6108

  Ooms, Marcel ^a   Krikoni, Aikaterini ^b   Kress, Andrea K ^c   Simon, Viviana ^a   Münk, Carsten ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Orthopedic Surgery   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3C; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3D; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3E; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; CYTIDINE DEAMINASE; UNCLASSIFIED DRUG; APOBEC3A PROTEIN, HUMAN; APOBEC3B PROTEIN, HUMAN; APOBEC3H PROTEIN, HUMAN; HYDROLASE; MUTANT PROTEIN; PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; MACACA MULATTA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA EDITING; SITE DIRECTED MUTAGENESIS; T CELL LEUKEMIA; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE; CELL LINE; ENZYME ACTIVE SITE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1;

AMINOHYDROLASES; CATALYTIC DOMAIN; CELL LINE; CYTIDINE DEAMINASE; HAPLOTYPES; HIV-1; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MUTANT PROTEINS; PROTEINS;

EID: 84863598092     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06570-11     Document Type: Article

References (93)

1. Adachi A, et al. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Albin JS, Harris RS. 2010. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 12:e4.
3. Bishop KN, Holmes RK, Malim MH. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80: 8450-8458.
4. Bishop KN, et al. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396.
5. Bogerd H, Wiegand H, Doehle B, Lueders K, Cullen B. 2006. APOBEC3A and APOBEC3B are potent inhibitors of LTRretrotransposon function in human cells. Nucleic Acids Res. 34:89-95.
6. Bogerd HP, Wiegand HL, Doehle BP, Cullen BR. 2007. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 364:486-493.
7. Bogerd HP, et al. 2006. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103:8780-8785.
8. Boross P, Bagossi P, Weber IT, Tozser J. 2009. Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection. Infect. Disord. Drug Targets 9:159-171.
9. Chen H, et al. 2006. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16:480-485.
10. Chiu YL, Greene WC. 2008. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26:317-353.
11. Conticello S, Harris R, Neuberger M. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013.
12. Dang Y, et al. 2008. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283:11606-11614.
13. Derse D, Hill SA, Lloyd PA, Chung H, Morse BA. 2001. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J. Virol. 75:8461-8468.
14. Derse D, Hill SA, Princler G, Lloyd P, Heidecker G. 2007. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc. Natl. Acad. Sci. U. S. A. 104:2915-2920.
15. de The G, Kazanji M. 1996. An HTLV-I/II vaccine: from animal models to clinical trials? J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13(Suppl. 1):S191-S198.
16. Doehle BP, Schafer A, Cullen BR. 2005. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339: 281-288.
17. Fan J, et al. 2010. APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J. Virol. 84:7278-7287.
18. Gessain A, et al. 1996. Virological aspects of tropical spastic paraparesis/HTLV-I associated myelopathy and HTLV-I infection. J. Neurovirol. 2:299-306.
19. Gibbs JS, Regier DA, Desrosiers RC. 1994. Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retroviruses 10:343-350.
20. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K. 2007. Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4:61.
21. Goila-Gaur R, Strebel K. 2008. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5:51.
22. Harari A, Ooms M, Mulder LC, Simon V. 2009. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83:295-303.
23. Harris RS, et al. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
24. Hlela C, Shepperd S, Khumalo NP, Taylor GP. 2009. The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown. AIDS Rev. 11:205-214.
25. Holmes RK, Koning FA, Bishop KN, Malim MH. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282:2587-2595.
26. Hultquist JF, et al. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85:11220-11234.
27. Igakura T, et al. 2003. Spread of HTLV-I between lymphocytes by virusinduced polarization of the cytoskeleton. Science 299:1713-1716.
28. Iwatani Y, et al. 2007. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35:7096-7108.
29. Izumo S, Umehara F, Osame M. 2000. HTLV-I-associated myelopathy. Neuropathology 20(Suppl.):S65-S68.
30. Janini M, et al. 2001. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4+ T cells. J. Virol. 75: 7973-7986.
31. Kao S, et al. 2004. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virusproducing cells. Retrovirology 1:27.
32. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE. 2007. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 3:e63.
33. Kijak GH, et al. 2008. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 376:101-111.
34. Koning FA, et al. 2009. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83:9474-9485.
35. Koralnik IJ, et al. 1994. Phylogenetic associations of human and simian T-cell leukemia/lymphotropic virus type I strains: evidence for interspecies transmission. J. Virol. 68:2693-2707.
36. Lecossier D, et al. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112.
37. Lee HH, et al. 1990. Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the Middle Atlantic and central regions of the USA. J. Infect. Dis. 162:347-352.
38. Li HC, et al. 2004. Provirus load in breast milk and risk of mother-tochild transmission of human T lymphotropic virus type I. J. Infect. Dis. 190:1275-1278.
39. Li HC, et al. 1999. The presence of ancient human T-cell lymphotropic virus type I provirusDNAin an Andeanmummy.Nat. Med. 5:1428-1432.
40. Mahieux R, Pecon-Slattery J, Gessain A. 1997. Molecular characterization and phylogenetic analyses of a new, highly divergent simian T-cell lymphotropic virus type 1 (STLV-1marc1) in Macaca arctoides. J. Virol. 71:6253-6258.
41. Mahieux R, et al. 2005. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J. Gen. Virol. 86:2489-2494.
42. Manel N, Battini JL, Taylor N, Sitbon M. 2005. HTLV-1 tropism and envelope receptor. Oncogene 24:6016-6025.
43. Mangeat B, et al. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
44. Mansky LM, et al. 2000. In vivo analysis of human T-cell leukemia virus type 1 reverse transcription accuracy. J. Virol. 74:9525-9531.
45. Mariani R, et al. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
46. Marin M, et al. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403.
47. Matsuoka M, Jeang KT. 2007. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer 7:270-280.
48. Mazurov D, Ilinskaya A, Heidecker G, Lloyd P, Derse D. 2010. Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Pathog. 6:e1000788.
49. Mbisa JL, et al. 2007. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81:7099-7110.
50. Mbisa JL, Bu W, Pathak VK. 2010. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J. Virol. 84:5250-5259.
51. Mehle A, et al. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.
52. Muckenfuss H, et al. 2006. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281:22161-22172.
53. Nagai M, Brennan MB, Sakai JA, Mora CA, Jacobson S. 2001. CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood 98:1858-1861.
54. Naldini L, et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
55. Narvaiza I, et al. 2009. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog. 5:e1000439.
56. Navarro F, et al. 2005. Complementary function of the two catalytic domains of APOBEC3G. Virology 333:374-386.
57. Newman EN, et al. 2005. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15:166-170.
58. OhAinle M, Kerns JA, Li MMH, Malik HS, Emerman M. 2008. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4:249-259.
59. Ohsugi T, Koito A. 2007. Human T cell leukemia virus type I is resistant to the antiviral effects of APOBEC3. J. Virol. Methods 139:93-96.
60. Okeoma CM, Huegel AL, Lingappa J, Feldman MD, Ross SR. 2010. APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe 8:534-543.
61. Ooms M, Majdak S, Seibert CW, Harari A, Simon V. 2010. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J. Virol. 84:7961-7969.
62. Ott DE. 2009. Purification of HIV-1 virions by subtilisin digestion or CD45 immunoaffinity depletion for biochemical studies. Methods Mol. Biol. 485:15-25.
63. Pais-Correia AM, et al. 2010. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat. Med. 16:83-89.
64. Peng G, et al. 2007. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110:393-400.
65. Pichler K, et al. 2008. Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients' T cells by the viral Tax oncoprotein. Blood 111:4741-4751.
66. Pichler K, Schneider G, Grassmann R. 2008. MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes. Retrovirology 5:100.
67. Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. 1981. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature 294:268-271.
68. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. 2005. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24:6058-6068.
69. Refsland EW, et al. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274-4284.
70. Ross SR. 2009. Are viruses inhibited by APOBEC3 molecules from their host species? PLoS Pathog. 5:e1000347.
71. Roucoux DF, et al. 2005. A prospective study of sexual transmission of human T lymphotropic virus (HTLV)-I and HTLV-II. J. Infect. Dis. 191: 1490-1497.
72. Ruckes T, Saul D, Van Snick J, Hermine O, Grassmann R. 2001. Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. Blood 98:1150-1159.
73. Rudolph DL, Yee J, Palker T, Coligan JE, Lal RB. 1993. Antibody responses to the env epitopes of human T-lymphotropic virus type I in rhesus macaques' naturally infected with simian T-lymphotropic virus type I. Res. Virol. 144:193-199.
74. Sasada A, et al. 2005. APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2:32.
75. Schmitt K, et al. 2011. Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution. Virology 419:24-42.
76. Sheehy A, Gaddis N, Choi J, Malim M. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
77. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407.
78. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. 2010. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17:222-229.
79. Suspène R, et al. 2011. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc. Natl. Acad. Sci. U. S. A. 108:4858-4863.
80. Suspène R, et al. 2011. Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J. Virol. 85:7594-7602.
81. Suspène R, et al. 2005. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:8321-8326.
82. Suspène R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP. 2005. Recovery of APOBEC3-edited human immunodeficiency virus G¡A hypermutants by differential DNA denaturation PCR. J. Gen. Virol. 86:125-129.
83. Tanaka G, et al. 2005. The clonal expansion of human T lymphotropic virus type 1-infected T cells: a comparison between seroconverters and long-term carriers. J. Infect. Dis. 191:1140-1147.
84. Van Dooren S, Salemi M, Vandamme AM. 2001. Dating the origin of the African human T-cell lymphotropic virus type-I (HTLV-I) subtypes. Mol. Biol. Evol. 18:661-671.
85. Van Prooyen N, et al. 2010. Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission. Proc. Natl. Acad. Sci. U. S. A. 107:20738-20743.
86. Vartanian JP, Guetard D, Henry M, Wain-Hobson S. 2008. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320:230-233.
87. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. 1991. Selection, recombination, and G¡A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 65:1779-1788.
88. Waldele K, et al. 2006. Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes. Blood 107:4491-4499.
89. Wang X, et al. 2011. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J. Virol. 85:3142-3152.
90. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
91. Wiegand HL, Cullen BR. 2007. Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins. J. Virol. 81:13694-13699.
92. Worobey M, et al. 2008. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 455:661-664.
93. Yu X, et al. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.